NSAIDs and Triptans – a (not) New Treatment Option for Migraine
Every day, around 7% of population will experience headache caused by migraine. Migraine is one of the leading causes of years lived with disability, and it also causes significant negative economic impact, as most as the affected population is of working age. Pathogenesis of migraine includes neur...
Saved in:
Main Authors: | B. Kakta, Rasa Mameniškienė |
---|---|
Format: | Article |
Language: | English |
Published: |
Vilnius University Press
2023-12-01
|
Series: | Neurologijos seminarai |
Subjects: | |
Online Access: | https://www.journals.vu.lt/neurologijos_seminarai/article/view/37597 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
The use of triptans as an effective form of migraine treatment – review
by: Agata Borkowska, et al.
Published: (2025-01-01) -
Effectiveness and tolerability of rimegepant in the acute treatment of migraine: a real-world, prospective, multicentric study (GAINER study)
by: Luigi Francesco Iannone, et al.
Published: (2025-01-01) -
Comparative Evaluation of Cyclooxygenase Inhibition Profiles Across Various NSAID Forms and Doses: Implications for Efficacy and Adverse Effects
by: Kenshu Shirakawa, et al.
Published: (2024-12-01) -
The impact of headache specialist density and the introduction of gepants and lasmitidan on prescriptions for acute migraine treatments: a regression and interrupted time series analysis
by: Leon S. Moskatel, et al.
Published: (2025-02-01) -
Epidemiology of clinically significant migraine in Israel: a retrospective database study
by: A. Shifrin, et al.
Published: (2025-02-01)